Status of Hepatitis B Virus Serological In Patients With Multipl Sclerosis Using Ocrelizumab

Yılmaz İnanç; Selçuk Nazik

Article Details

Status of Hepatitis B Virus Serological In Patients With Multipl Sclerosis Using Ocrelizumab

Authors:

Yılmaz İnanç | Selçuk Nazik

Publisher:

Kahramanmaras Sutcu Imam University

Main Topics:

Sağlık Kurumları Yönetimi

Journal:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 3, pp.51-54

Document Type:

Article

Publication Date:

11/2023

Document Language:

English

Document ID (Org No.):

2001303778

pISSN:

1303-6610

Keywords:

Abstract:

 Objective: B-cell depleting treatments are associated with potential risks of viral infections. Hepatitis B virus HBV infection is the most common chronic viral infection and it is estimated that 30 of the world population has serological evidence of current or past infection. Material and Methods: Our study is a single-center, cross-sectional study. We retrospectively reviewed the clinical records of MS patients receiving ocrelizumab. Demographic and clinical characteristics of patients, Expanded Disability Status Scale EDSS, drug history before ocrelizumab for MS; Mean ocrelizumab intake times, smoking status, hepatitis C virus, HIV serological status, HBV serological status, HBV treatment status were recorded. Results: The study included 64 MS patients treated with Ocrelizumab. The mean age was 41.69.8 years min-max: 21-62 years. 75 of the cases were female n:48, 25 were male n:16. HIV and hepatitis C virus serological tests were negative in all cases. HBsAg was found to be positive in 1.6 n:1 and Anti-HBcIgG in 12.5 n:8. The number of patients who were started on hepatitis B treatment was 12.5 n:8, and tenofovir disoproxil was started in 2 patients 25, entecavir in 5 patients 62.5, and tenofovir alafenamide in 1 patient 12.5. The mean duration of taking ocrelizumab for the patients was 28.513.1 months min-max: 6-46 months. Conclusion: In conclusion, all patients should be screened for HBV before starting ocrelizumab therapy. Both HBsAg and Anti-HBcIg G tests should be used. The isolated presence of Anti-HBcIg G may cause HBV reactivation. Therefore, Anti-HBcIg G should be screened before immunosuppressive therapy.

 Objective: B-cell depleting treatments are associated with potential risks of viral infections. Hepatitis B virus HBV infection is the most common chronic viral infection and it is estimated that 30 of the world population has serological evidence of current or past infection. Material and Methods: Our study is a single-center, cross-sectional study. We retrospectively reviewed the clinical records of MS patients receiving ocrelizumab. Demographic and clinical characteristics of patients, Expanded Disability Status Scale EDSS, drug history before ocrelizumab for MS; Mean ocrelizumab intake times, smoking status, hepatitis C virus, HIV serological status, HBV serological status, HBV treatment status were recorded. Results: The study included 64 MS patients treated with Ocrelizumab. The mean age was 41.69.8 years min-max: 21-62 years. 75 of the cases were female n:48, 25 were male n:16. HIV and hepatitis C virus serological tests were negative in all cases. HBsAg was found to be positive in 1.6 n:1 and Anti-HBcIgG in 12.5 n:8. The number of patients who were started on hepatitis B treatment was 12.5 n:8, and tenofovir disoproxil was started in 2 patients 25, entecavir in 5 patients 62.5, and tenofovir alafenamide in 1 patient 12.5. The mean duration of taking ocrelizumab for the patients was 28.513.1 months min-max: 6-46 months. Conclusion: In conclusion, all patients should be screened for HBV before starting ocrelizumab therapy. Both HBsAg and Anti-HBcIg G tests should be used. The isolated presence of Anti-HBcIg G may cause HBV reactivation. Therefore, Anti-HBcIg G should be screened before immunosuppressive therapy.

 Objective: B-cell depleting treatments are associated with potential risks of viral infections. Hepatitis B virus HBV infection is the most common chronic viral infection and it is estimated that 30 of the world population has serological evidence of current or past infection. Material and Methods: Our study is a single-center, cross-sectional study. We retrospectively reviewed the clinical records of MS patients receiving ocrelizumab. Demographic and clinical characteristics of patients, Expanded Disability Status Scale EDSS, drug history before ocrelizumab for MS; Mean ocrelizumab intake times, smoking status, hepatitis C virus, HIV serological status, HBV serological status, HBV treatment status were recorded. Results: The study included 64 MS patients treated with Ocrelizumab. The mean age was 41.69.8 years min-max: 21-62 years. 75 of the cases were female n:48, 25 were male n:16. HIV and hepatitis C virus serological tests were negative in all cases. HBsAg was found to be positive in 1.6 n:1 and Anti-HBcIgG in 12.5 n:8. The number of patients who were started on hepatitis B treatment was 12.5 n:8, and tenofovir disoproxil was started in 2 patients 25, entecavir in 5 patients 62.5, and tenofovir alafenamide in 1 patient 12.5. The mean duration of taking ocrelizumab for the patients was 28.513.1 months min-max: 6-46 months. Conclusion: In conclusion, all patients should be screened for HBV before starting ocrelizumab therapy. Both HBsAg and Anti-HBcIg G tests should be used. The isolated presence of Anti-HBcIg G may cause HBV reactivation. Therefore, Anti-HBcIg G should be screened before immunosuppressive therapy.

 Amaç: B-hücresi tüketen tedaviler, potansiyel viral enfeksiyon riskleri ile ilişkilidir. Hepatit B virüsü HBV enfeksiyonu en yaygın kronik viral enfeksiyondur ve dünya nüfusunun tahminen 30unun mevcut veya geçmiş enfeksiyona ilişkin serolojik kanıtlara sahip olduğu tahmin edilmektedir. Gereç ve Yöntemler: Çalışmamız tek merkezli, retrospektif, kesitsel bir çalışmadır. ocrelizumab alan Multiple Skleroz MS hastalarının klinik kayıtlarını geriye dönük olarak inceledik. Hastaların demografik ve klinik özellikleri, Ortalama Expanded Disability Status Scale EDSS, MS için ocrelizumab öncesi ilaç geçmişi; ortalama ocrelizumab alma süreleri, sigara kullanım durumu, Hepatit C virüs, HIV serolojik durumları, HBV serolojik durumu, HBV tedavi durumu kaydedildi. Bulgular: Çalışmaya ocrelizumab ile tedavi edilen 64 MS hastası dahil edildi. Ortalama yaş 41.69.8 yıl min-max: 21-62 yıl idi. Olguların 75i kadın n:48, 25i erkek n:16 idi. Olguların tümünde HIV, Hepatit C virüs serolojik testleri negatif idi. HBsAg 1.6 n:1, Anti HBcIgG 12.5 n:8 oranında pozitif saptandı. Hepatit B tedavisi başlanan hasta sayısı 12.5 n:8 olup, 2 hastaya 25 tenofovir disoproksil, 5 hastaya 62.5 entekavir, 1 hastaya 12.5 tenofovir alafenamid tedavisi başlanmıştır. Hastaların ortalama ocrelizumab alma süreleri 28.513.1 ay min-max:6-46 ay olarak saptandı. Sonuç: Sonuç olarak, ocrelizumab tedavisine başlamadan önce tüm hastalarda HBV taraması yapılmalıdır. Hem HBsAg hem de Anti-HBcIg testleri kullanılmalıdır. Anti-HBcIg Gnin varlığı HBV reaktivasyonunu engellemez, bu nedenle immünosupresif tedaviden önce Anti-HBcIg açısından mutlaka taranmalıdır.

Article Details

Status of Hepatitis B Virus Serological In Patients With Multipl Sclerosis Using Ocrelizumab

Authors:

Yılmaz İnanç | Selçuk Nazik

Publisher:

Kahramanmaras Sutcu Imam University

Main Topics:

Sağlık Kurumları Yönetimi

Journal:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 3, pp.51-54

Document Type:

Article

Publication Date:

11/2023

Document Language:

English

Document ID (Org No.):

2001303778

pISSN:

1303-6610

multiple sclerosis

ocrelizumab

hepatitis B virusMultipl skleroz

ocrelizumab

hepatit B virüs

Issues

Article Details

Status of Hepatitis B Virus Serological In Patients With Multipl Sclerosis Using Ocrelizumab

Authors: Yılmaz İnanç | Selçuk Nazik

Publisher: Kahramanmaras Sutcu Imam University

Main Topics: Sağlık Kurumları Yönetimi

Journal: Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 3, pp.51-54

Document Type: Article

Publication Date: 11/2023

Document Language: English

Document ID (Org No.): 2001303778

pISSN: 1303-6610

multiple sclerosis

ocrelizumab

hepatitis B virusMultipl skleroz

ocrelizumab

hepatit B virüs

Issues

Authors:

Yılmaz İnanç | Selçuk Nazik

Publisher:

Kahramanmaras Sutcu Imam University

Main Topics:

Sağlık Kurumları Yönetimi

Journal:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 3, pp.51-54

Document Type:

Article

Publication Date:

11/2023

Document Language:

English

Document ID (Org No.):

2001303778

pISSN:

1303-6610